Biblio

Author Title [ Type

] Year

Filters: Author is Zhang, Yanming [Clear All Filters]

Journal Article

Diamond BT, Ziccheddu B, Maclachlan KH, Taylor J, Boyle EMary, Ossa JEsteban Ar, Jahn TJacob, Affer M, Totiger TM, Coffey DG, et al. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. Blood. 2023.

DeWolf S, Elhanati Y, Nichols K, Waters NR, Nguyen CL, Slingerland JB, Rodriguez N, Lyudovyk O, Giardina PA, Kousa AI, et al. Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse. Sci Transl Med. 2023;15(706):eabq0476.

Miltiadous O, Petrova-Drus K, Kaicker S, Mathew S, Kluk M, Geyer JTurbiner, M Rodriguez-Sanchez I, Bouvier N, Inghirami GGa, Stieglitz E, et al. Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. Blood Adv. 2021.

Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology. 2023;28(1):2212534.

Wei X, Chang Y, Zhu X, Hu X, Guo R, Zhang Y, Ma X, Han Y, Wang Y, Qiu H, et al. The impact of pre-transplant anti-HLA antibodies in transplants from HLA-identical sibling donors: A multicenter study. HLA. 2023.

Vanoli F, Herviou L, Tsuda Y, Sung P, Xie Z, Fishinevich E, Min SS, Mallen W, de Wardin Hde Traux, Zhang Y, et al. Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy. Oncogenesis. 2023;12(1):8.

Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao JJ, Casanova J, Lin Y-TDavid, Petrova-Drus K, Mohanty AS, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nat Commun. 2023;14(1):6895.

Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2023.

Ning Y, Zhang Y, Kallen MA, Emadi A, Baer MR. Cytogenetics and molecular genetics of myelodysplastic neoplasms. Best Pract Res Clin Haematol. 2023;36(4):101512.

Liu L, Xu G, Zhang Y, Jiao W, Lei M, Zhou H, Wang Q, Qiu H, Tang X, Han Y, et al. Comparison of two different rabbit antithymocyte globulin (r-ATG) preparations:Thymocyte r-ATG versus T lymphoblast cell line r-ATG in allogeneic hematopoietic stem cell transplantation for acquired severe aplastic anemia: propensity score-matched analysi. Biol Blood Marrow Transplant. 2020.

Zhang Y, Liu L, Si Y, Miao M, Qiu H, Tang X, Han Y, Fu C, Jin Z, Chen S, et al. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia. Hematology. 2021;26(1):741-750.